MarketOpen Podcast Episode 52 - Argenica Therapeutics

In this episode, we sit down with Dr Liz Dallimore, who serves as the Chief Executive Officer and Managing Director of Argenica Therapeutics (ASX:AGN). Join us as we delve into the most recent developments and valuable insights within AGN, and take a closer look at what drives Liz's success.Dr Dallimore has over 20 years’ experience in both biotechnology and management consulting across Australia and the UK. She has held senior roles in management consulting as KPMG’s Australian Director of Research Engagement and Commercialisation, structuring technology commercialisation deals across a range of sectors, with a specific focus on biotechnology. Prior to this Liz held senior management roles with Ernst & Young and PricewaterhouseCoopers in technology advisory and R&D. Prior to moving into management consulting, Liz was a research scientist at the Australian Neuromuscular Research Institute (now the Perron Institute of Neurological & Translational Sciences) and the UK’s Food Standard’s Agency.Dr Dallimore is also a Non-Executive director of the Chamber of Commerce and Industry WA and AusBiotech, as well as and Industry Advisor to the Telethon Kids Institute’s Innovation and Commercialisation Committee and member of the Stan Perron Charitable Foundation’s Health Research Advisory Panel advising on child health research funding.Dr Dallimore holds a PhD in Neuroscience jointly completed at Oxford University and the University of Western Australia, an MBA from the Australian Graduate School of Management, and is a Member of the Australian Institute of Company Directors.